|
|
||||||||
Department of Pediatrics, Georgetown University School of Medicine, Washington DC, USA
Correspondence
Itzhak Brook
ib6{at}georgetown.edu
Received 23 June 2006
Accepted 24 August 2006
Abbreviations: BLPB, ß-lactamase-producing bacteria; GABHS, group A ß-haemolytic streptococci; PT, pharyngo-tonsillitis.
| INTRODUCTION |
|---|
|
|
|---|
Children are the major reservoir of GABHS and are the target population for PT, as well as its suppurative and non-suppurative complications (O'Brien et al., 2002). Carriers of GABHS harbour the organism in their nose or throat but display no symptoms of acute infection. They represent the pool from which patients with severe invasive disease may acquire their infections (Cockerill et al., 1997). The reasons that lead to the GABHS carrier state are not yet established.
Penicillin therapy is only 30 % effective in eradicating the carrier state (Tanz et al., 1985), as compared to over 90 % for clindamycin therapy (Tanz et al., 1991). The presence of ß-lactamase-producing bacteria (BLPB) in the tonsils, which protect GABHS from penicillin by inactivating the antibiotic, was offered as one of the explanation for penicillin failure in eradication of an acute GABHS tonsillitis (Brook, 1984). The presence of BLPB in the tonsillar flora of GABHS carriers was not previously studied.
An inverse relationship has been found between the presence of aerobic and anaerobic organisms with interfering capability against GABHS and the isolation of this organism from the tonsils (Brook & Gober, 1999). These bacteria have been shown in vitro to compete and thus interfere with GABHS growth (Crowe et al., 1973). The prevalence of these interfering organisms has never been evaluated in GABHS carriers.
The purpose of the present study was to compare the frequency of recovery of aerobic and anaerobic organisms with interfering capability against GABHS as well as BLPB from the tonsils of GABHS carriers and non-carriers. The carriers of GABHS included healthy children that were seen for their annual physical examination and those recently treated for symptomatic GABHS PT with penicillin that failed to eradicate the GABHS.
| METHODS |
|---|
|
|
|---|
Both tonsillar surfaces were swabbed with two sterile cotton swabs. Aerobic cultures were obtained by placing a swab in modified Stuart's bacterial transport system (Baltimore Biological Laboratories). Cultures for anaerobes were obtained by introducing a swab into anaerobic transport medium (Port-A-Cul; Becton Dickinson Labware). The specimens were inoculated within 2 h of collection.
Sheep's blood (5 %), chocolate and MacConkey agar plates were inoculated for the isolation of aerobic organisms. The culture plates were incubated aerobically at 37 °C (MacConkey agar) and under 5 % carbon dioxide (blood and chocolate agars), and they were examined at 24 and 48 h. For the recovery of anaerobic bacteria, the specimens were inoculated onto pre-reduced vitamin K1-enriched Brucella blood agar, blood agar that contained kanamycin and vancomycin, and an aerobic blood plate that contained phenylethyl alcohol and enriched thioglycolate broth. These media were immediately incubated in GasPak jars (Baltimore Biological Laboratories) at 37 °C, and examined after 48 and 96 h of incubation at 37 °C. All types of colonies on each plate were isolated. Aerobic and anaerobic bacteria were identified by published methods (Summanen et al., 1995; Murray et al., 2003). ß-Lactamase activity was determined for five colonies of each of the anaerobic and aerobic isolates by using a cefinaz disk (Baltimore Biological Laboratories).
Testing for interference. The inhibitory activity of five separate colonies from all aerobic and anaerobic isolates was evaluated by individually testing against one strain of a recent clinical isolate of S. pyogenes, using a Steer's steel pin replicator as described by Grahn et al. (1983). In brief, minidrops of exponential-phase broth cultures of the isolates were transferred with the pin replicator to vitamin K1-enriched Brucella blood agar plates and allowed to dry for 15 min at room temperature. A sample of a exponential-phase broth culture of the S. pyogenes strain was applied adjacent to each of the isolated strains, and the plates were incubated in 5 % carbon dioxide or anaerobically at 37 °C for 48 h. Bacterial interference was defined as any reproducible inhibition of growth. Degrees of inhibition varied from complete absence of growth to a narrow zone of poor growth along the proximal area of the colony. Statistical significance was calculated by Fishers exact test (two-sided) unadjusted.
| RESULTS |
|---|
|
|
|---|
-streptococci, non-haemolytic streptococci, Prevotella spp. and Peptostreptococcus spp.) were recovered from sixteen (80 %) non-GABHS carriers (1.6 per child) and thirteen were isolated from seven (35 %) GABHS carriers (0.65 per child) (P<0.001, when comparing the proportion of children with interfering organisms) (Table 1
|
BLPB
Children seen for annual examination (group 1).
Thirteen BLPB (including Staphylococcus aureus, Moraxella catarrhalis, Haemophilus influenzae non-type b, Haemophilus parainfluenzae, Prevotella spp., Porphyromonas spp. and Fusobacterium spp.) were recovered from five (25 %) non-GABHS carriers (0.65 per child) and thirteen were isolated from six (30 %) GABHS carriers (0.65 per child) (Table 2
).
|
| DISCUSSION |
|---|
|
|
|---|
These findings shed light on the unique bacterial flora of non-GABHS carriers and GABHS carriers, those who had no recent PT (group 1) and those who did suffer from GABHS PT and were recently treated with penicillin (group 2).
The association between the presence of high number of BLPB and colonization of the tonsils by GABHS in patients who were recently treated with penicillin, is explained by the protection provided to GABHS from the antibiotic (Brook, 1984). Recently treated patients who were not carriers were less likely to harbour BLPB. These findings are in concert with the clear association that has been established in the therapy of GABHS PT between the failure of patients to respond to penicillin, and the pre-existence of BLPB (Brook, 1984). Over 3/4 of tonsils removed due to recurrent tonsillitis, harbour BLPB and free ß-lactamase was detected in the core of the majority of those tonsils.
There is an intricate balance in the oropharynx between potential pathogens, including GABHS and interfering organisms. The relative paucity of interfering organisms in GABHS carriers occurred in healthy children as well as children recently treated for PT. The protective ability of interfering organisms may therefore play a role in the prevention of the carrier state. Prevention of upper respiratory bacterial infections is partially achieved because of the ability of members of the normal oropharyngeal flora to deter colonization and subsequent infection by those pathogens. The oropharynx flora of individuals who are not GABHS tonsillitis prone contains more organisms that are capable of interfering with the in vitro growth of potential pathogens than those who are GABHS tonsillitis prone (Brook & Gober, 1995, 1999). Only about 30 % of patients who suffer from recurrent GABHS tonsillitis are colonized with organisms that are capable of interfering with GABHS (Brook & Gober, 1995, 1999). On the other hand, 85 % of individuals who stay GABHS PT free are colonized by those protective organisms. This phenomena of protection is called bacterial interference (Brook, 2005; Grahn et al., 1983). The present study suggests that the in vitro interference phenomena also may have in vivo correlates in children who are GABHS carriers.
The normal flora interferes with colonization and subsequent infection by pathogens through various mechanisms. These include competition on nutritional substances, and the production of antibiotic-like substances that kill other bacteria called bacteriocins (Brook, 2005; Grahn et al., 1983; Walls et al., 2003). The major protective organisms are
- and
-haemolytic streptococci, Peptostreptococcus spp. and Prevotella spp. These organisms play a homeostatic role by colonizing the tonsils in sufficient numbers that they prevent colonization and infection by GABHS.
Therapeutic colonization of the nasopharynx with interfering bacteria was studied by Roos et al. (1996) who colonized 112 children with repeated tonsillitis with either
-haemolytic streptococci or placebo. Recurrences occurred in 1 of 51 children (2 %) in the
-haemolytic streptococci group and 14 of 61 children (23 %) in the placebo group.
Antibiotics that possess broad activity against interfering organisms may reduce their numbers in the oral flora (Brook & Gober, 1995; Brook, 2001). Pichichero et al. (1999) found that the GABHS carrier rate is higher following treatment of acute GABHS PT with penicillin (11.3 %), than with an oral cephalosporin (4.3 %) (P<0.001). The cephalosporin group of antibiotics have been successful in eradicating GABHS better, and in some instances much faster, than penicillin (Casey & Pichichero, 2004). Over 50 studies show that all classes and types of cephalosporins have a much higher success rate in eradicating GABHS than penicillin (Casey & Pichichero, 2004). The explanation for the ability of cephalosporins to perform so well is that in addition to their efficacy against GABHS they are less effective against the interfering organisms (Brook & Foote, 2005). They are less active than penicillins against anaerobic bacteria (Finegold & Sutter, 1976) and
-haemolytic streptococci (Brook & Foote, 2005).
Our data suggest that bacterial interference and ß-lactamase production may play a role in the presence of the GABHS carrier state. Further studies are warranted to evaluate how modulation of the normal flora can prevent the GABHS carrier state.
| REFERENCES |
|---|
|
|
|---|
-hemolytic streptococci isolated from tonsillar surface on ß-hemolytic streptococci (Streptococcus pyogenes) a methodological study. Zentralbl Bakteriol Mikrobiol Hyg A 254, 459468.
-streptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis a randomized placebo-controlled multicenter study. Scand J Infect Dis 28, 459462.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |